Synergistic Cardiopulmonary Protection of Endothelin Receptor Antagonists Combined With Soluble Guanylate Cyclase Agonists in High-Risk Coronary Syndrome With Pulmonary Hypertension

Read full text Summarise with VIRAT
Authors: Liyue Zhao, Xinli Pang
Cited by: 0
References: 35

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: The prognosis and long-term survival of high-risk coronary syndrome patients with pulmonary hypertension (PH) remain unsatisfactory, and limited research has evaluated the synergistic therapeutic effects of endothelin receptor antagonists (ERAs) combined with soluble guanylate cyclase agonists (sGCAs). This study aimed to assess the synergistic cardiopulmonary protective effects and clinical safety of ERA combined with sGCA therapy in patients with high-risk coronary syndrome complicated by PH. Methods: This retrospective controlled study included 132 patients with high-risk coronary syndrome and PH who were admitted between January 2019 and December 2023. After exclusion criteria were applied, 119 patients were analyzed and categorized into a control group (ambrisentan monotherapy, n = 58) and an experimental group (ambrisentan plus riociguat, n = 61) according to the associated treatment strategy. Primary endpoints included 6-minute walk distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and the World Health Organization-related functional class (WHO-FC). Secondary endpoints included cardiac index (CI), left ventricular end-diastolic diameter (LVEDD), tricuspid annular plane systolic excursion (TAPSE), mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), Borg dyspnea score (BDS), and the incidence of adverse events. Results: Baseline characteristics between the two groups were comparable (all p > 0.05). Following treatment, the 6MWD, CI, and TAPSE values significantly improved in both groups (all p < 0.05), with greater improvements observed in the experimental group (95% CI: –3.61 to –0.05, p = 0.044; 95% CI: –0.20 to –0.004, p = 0.039; 95% CI: –0.29 to –0.07, p = 0.001). The NT-proBNP, LVEDD, mPAP, PVR, and BDS values decreased in both cohorts (all p < 0.05), with more pronounced reductions in the experimental group (95% CI: 0.02–3.5, p = 0.048; 95% CI: 0.03–0.21, p = 0.012; 95% CI: 0.02–2.03, p = 0.046; 95% CI: 0.65–4.30, p = 0.008; 95% CI: 0.06–0.78, p = 0.022). The proportion of individuals in the WHO-FC classes III–IV was lower in the experimental group (95% CI: 1.05–4.56, p = 0.035). No statistically significant difference in adverse-event incidence was observed between groups (95% CI: 0.73–5.03, p = 0.184). Conclusion: Combination therapy with ambrisentan and riociguat effectively improved cardiopulmonary function and clinical outcomes in patients with high-risk coronary syndrome and PH, offering a promising therapeutic strategy for this population. This study is a single-center retrospective study, which inherently limits the credibility of causal inference; therefore, the results need to be further verified by multi-center, large-sample prospective studies.

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments Heart Failure Treatment and Management Vascular Anomalies and Treatments

Publication details

Journal / source
Reviews in Cardiovascular Medicine
Volume
27
Issue
3
Pages
46401–46401
Publication date
16 March 2026
Language
EN